Nasdaq Panel finds CERo Therapeutics again compliant with $2.5M equity rule

CERO THERAPEUTICS HOLDINGS, INC.

On May 7, 2025, Nasdaq Hearings Panel determined CERo complied with Listing Rule 5550(b)(1) (minimum $2.5M stockholders' equity).
Compliance achieved through Series D Preferred private placement (4/21/2025), Equity Line drawdown, and public offering in Feb 2025.
CEO Chris Ehrlich says company now focused on lead program CER-1236; anticipates first patient dose in Phase 1 trial soon.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.